Novo Nordisk A/S, member of the Supervisory Board since 2007, appointed Marcus Schindler as its representative to serve on our Supervisory Board in 2018. Mr Schindler is Senior Vice President External Innovation & Strategy at Novo Nordisk A/S.
Prior to this occupation, Mr. Schindler was VP, Head of the Cardiovascular & Metabolic Diseases and Head of Research at Novo Nordisk A/S. Previously he was member of Executive Management Committee, (OSI) Prosidion, based in Oxford, UK, held senior positions at Boehringer Ingelheim and at Glaxo Wellcome’s blue skies research institute, “Glaxo Institute of Applied Pharmacology”, Cambridge, UK.
Mr. Schindler received his PhD in Pharmacology from the University of Cambridge and holds a position as adjunct Professor of Pharmacology at the University of Gothenburg. He as co-/authored 50+ peer-reviewed research papers and is an inventor of 25 international patent applications.